科兴制药: 自愿披露关于GB08注射液II期临床试验完成首例受试者入组的公告

Group 1 - The core point of the announcement is that Kexing Biopharmaceutical Co., Ltd. has successfully completed the enrollment of the first subject in the Phase II clinical trial of its self-developed GB08 injection, which is aimed at treating children with growth hormone deficiency [1][2] - GB08 injection is the company's first independently developed Class I innovative drug, designed as a long-acting growth hormone based on the needs of clinical patients [1][2] - The clinical trial for GB08 injection has received ethical approval from Zhejiang University School of Medicine Affiliated Children's Hospital, and the trial is a multi-center, randomized, open-label, positive-controlled Phase II/III study [2] Group 2 - The successful enrollment of the first subject in the Phase II clinical trial is not expected to have a significant impact on the company's recent financial status or operating performance [2] - The company will continue to monitor the progress of the GB08 injection and fulfill its disclosure obligations in accordance with relevant regulations [2]